A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 6, 1999, Pages 1189-1197

  Kemp, James P ^a   DeGraff Jr , Arthur C ^b   Pearlman, David S ^c   Wang, Yonghua ^d   Arledge, Teresa E ^d   Welch, Mary Beth ^d   O'Riordan, Thomas G ^d   Herrle, Myra Rosario ^d   Stahl, Edmundo G ^d  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b Hartford Lung Physicians Research Center   (United States)

^c Respiratory Institute   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma therapy; Bronchial hyperresponsiveness; Methacholine; Placebo; Pulmonary function; Salmeterol xinafoate powder

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; METHACHOLINE; SALBUTAMOL; SALMETEROL XINAFOATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SELF REPORT; TREATMENT OUTCOME;

EID: 0033431828     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70012-6     Document Type: Article

References (35)

1. 1. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel long acting beta2-agonist. Ann Pharmacother 1993;217:1478-87.
2. 2. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. Comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. New Engl J Med 1992;327:1420-53.
3. 3. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard S. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994;271:1412-6.
4. 4. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992;5:1062-7.
5. 5. Nathan RA, Seltzer JS, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, et al. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol 1995;75:243-8.
6. 6. Burrows B, Lebowitz MD. The β-2 agonist dilemma. N Engl J Med 1992;326:560-1.
7. 7. Wanner A, Sears M. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? Am J Respir Crit Care Med 1995;151:597-9.
8. 8. O'Byrne PM, Kerstjens HAM. Inhaled beta2-agonists in the treatment of asthma. N Engl J Med 1996;335:886-8.
9. 9. Sears MR, Taylor DR, Print CG, Lake DC, Li Q, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
10. 10. Drazen J, Israel E, Boushey H, Chinchilli V, Fahy J, Fish J, et al. Comparison of regularly scheduled with as-needed albuterol in mild asthma. N Engl J Med 1996;335:841-7.
11. 11. Spizer W, Suissa S, Ernst P, Horowitz R, Harbick B, Cockcroft D, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
12. 12. Van Schayck CP, Dompeling E, Van Herwaarden CLA, Folgering H, Verbeek AL, Van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study. BMJ 1991;303:1426-31.
13. 13. Van Schayck CP, Graafsmaj SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CLA. Increased bronchial hyperresponsiveness after inhaling salbutamol during one year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990;86:793-800.
14. 14. Vathenen AS, Higgins BG, Knox AJ, Britton JR, Tattersfield AE. Rebound increase in bronchial hyperresponsiveness after treatment with inhaled terbutaline. Lancet 1988;1:55-7.
15. 15. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655-9.
16. 16. Cockroft D, Swysun V, Bhagat R. Interaction of inhaled β2 agonist and inhaled corticosteroid on inhaled responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995;152:1485-9.
17. 17. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effects of a long-acting β2 agonist. Am J Respir Crit Care Med 1996;154:1603-7.
18. 18. Cheung D, Timmers MC, Zwinderman AH, Bel HE, Dijkman JH, Sterk PJ. Long-term effects of a long acting β-2 adrenoceptor agonist salmeterol on methacholine induced bronchoconstriction. N Engl J Med 1992;327:1198-203.
19. 19. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta-2 agonists in asthma. N Engl J Med 1992;327:1204-8.
20. 20. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
21. 21. Rosenthal RR. Approved methodology for methacholine challenge. Allergy Proc 1989;10:301-12.
22. 22. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7.
23. 23. Verberne APH, Hop WCJ, Bos AB, Kerrebijn KF. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. J Allergy Clin Immunol 1993;91:127-34.
24. 24. Peat JK, Unger WR, Combe D. Measuring changes in logarithmic data, with special reference to bronchial responsiveness. J Clin Epidemiol 1994;47:1099-108.
25. 25. 1997 Montreal Protocol on Substances that Deplete the Ozone Layer (amended in Montreal, 1997). Nairobi, Kenya: The Ozone Secretariat; 1997. United Nations Environment Programme.
26. 26. Gongora HC, Wisniewski AFZ, Tattersfield AE. A single dose comparison of inhaled albuterol and two formulations of salmeterol in asthmatic subjects. Am Rev Respir Dis 1991;144:626-9.
27. 27. Brindley A, Sumby B, Smith IJ, Prime D, Haywood P, Grant AC. Design, manufacture and dose consistency of the Serevent Diskus inhaler. Pharmaceutical Technology Europe 1995;7:14-22. Publication No.: PTE 9053.
28. 28. Simons FER, Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
29. 29. Repscher I, Anderson J, Bush R, Falliers C, Kass I, Kemp J, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984;85:34-8.
30. 30. Barnes PJ. State of the art beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-60.
31. 31. Tattersfield AE. Measurement of bronchial reactivity: a question of interpretation. Thorax 1981;36:561-5.
32. 32. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung and Blood Institute, National Institutes of Health; 1997. Publication No.: 97-4051.
33. 33. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
34. 34. Woolcock, A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
35. 35. Verberne A, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One-year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-95.